Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

ConclusionNIC was unlikely to be cost-effective as a first-line treatment for patients with advanced NSCLC.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research